Abiopharma

PRESTIGE CONSUMER HEALTHCARE INC. (PBH) Reports the reporting period Financial Results PRESTIGE CONSUMER HEALTHCARE INC. (PBH) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 281617
• Net Income: 9405
• EPS: 4.42
• Cash and equivalents: 63868
  • expected ongoing depreciation levels once the facility is fully remediated and operating at normal production levels.(b) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. As a result, normal overhead absorption levels were not achieved, leading to elevated unit costs. Management believes these costs are not indicative of the Company’s expected ongoing operating cost structure once the facility is fully remediated and operating at normal production levels.Reconciliation of GAAP General and Administrative Expense and related GAAP General and Administrative Expense percentage to Non-GAAP Adjusted General and Administrative expense and related Non-GAAP Adjusted General and Administrative Expense percentage:Three Months Ended March 31, Year Ended March 31,2026
  • expected ongoing operating cost structure once the facility is fully remediated and operating at normal production levels.(b) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees.Reconciliation of GAAP Net Income and GAAP Diluted Earnings Per Share to Non-GAAP Adjusted Net Income and related Non-GAAP Adjusted Diluted Earnings Per Share: Three Months Ended March 31,Year Ended March 31,2026
  • expected ongoing depreciation levels once the facility is fully remediated and operating at normal production levels.Reconciliation of GAAP Net Income to Non-GAAP EBITDA and related Non-GAAP EBITDA Margin, Non-GAAP Adjusted EBITDA and related Non-GAAP Adjusted EBITDA Margin:Three Months Ended March 31,Year Ended March 31,2026